

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313 on August 28, 2006



INFORMATION DISCLOSURE
STATEMENT
Examining Group 1654
Patent Application
Docket No. G-175US03PCT
Serial No. 10/510,002

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1654
Applicants : Kristen Briggs, Deno Dialynas, John Lucas, Aaron Scalia
Serial No. : 10/510,002
Filed : September 29, 2004
Conf. No. : 7745
For : XCRF Polynucleotides and Polypeptides and Uses Thereof

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313


INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 U.S.C. § 371. Applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notice of Acceptance of the Application Under 35 USC 371 (Form PCT/DO/EO/903). The Notice does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. In accordance with 37 C.F.R. § 1.56, Applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachment: Form PTO/SB/08; copies of cited references.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/510,002 |
| | | | | Filing Date | September 29, 2004 |
| | | | | First Named Inventor | Kristen Briggs |
| | | | | Art Unit | 1654 |
| | | | | Examiner Name | |
| Sheet | 1 | of | 2 | Attorney Docket Number | G-175US03PCT |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | U1 | US- | | | |
| | U2 | US- | | | |
| | U3 | US- | | | |
| | U4 | US- | | | |
| | U5 | US- | | | |
| | U6 | US- | | | |
| | U7 | US- | | | |
| | U8 | US- | | | |
| | U9 | US- | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | F1 | WO 01/79454 A1 | 10-25-2001 | SmithKline Beecham Corporation | All | |
| | F2 | WO 02/04600 A | 01-17-2002 | SmithKline Beecham Corporation | All | |
| | F3 | WO 02/048337 A | 06-20-2002 | Incyte Genomics, Inc. | All | |
| | F4 | WO 02/079398 A | 10-10-2002 | Curagen Corporation | All | |
| | F5 | WO 02/057450 A | 07-25-2002 | Curagen Corporation | All | |
| | F6 | | | | | |
| | F7 | | | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 10/510,002 | |
| | | | Filing Date | September 29, 2004 | |
| | | | First Named Inventor | Kristen Briggs | |
| | | | Group Art Unit | 1654 | |
| | | | Examiner Name | | |
| Sheet | 2 | of | 2 | Attorney Docket Number | G-175US03PCT |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | R1 | BARSH, G. S. <i>et al.</i> "Genetics of Body-Weight Regulation" <i>Nature</i> , April 6, 2000, pp. 644-651, Vol. 404. | |
| | R2 | BERUBE, N. G. <i>et al.</i> "Cloning and Characterization of CRF, a Novel C1q-Related Factor, Expressed in Areas of the Brain Involved in Motor Function" <i>Molecular Brain Research</i> , January 8, 1999, pp. 233-240, Vol. 63, No. 2. | |
| | R3 | CESARMAN, E. <i>et al.</i> "Kaposi's Sarcoma-Associated Herpesvirus-Like DNA Sequences in AIDS-Related Body-Cavity-Based Lymphomas" <i>New England Journal of Medicine</i> , May 4, 1995, pp. 1186-1191, Vol. 332, No. 18. | |
| | R4 | DUNAIF, A. <i>et al.</i> "The Insulin-Sensitizing Agent Troglitazone Improves Metabolic and Reproductive Abnormalities in the Polycystic Ovary Syndrome" <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, pp. 3299-3306, Vol. 81, No. 9. | |
| | R5 | EHRMANN, D. A. <i>et al.</i> "Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome" <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, pp. 2108-2116, Vol. 82, No. 7. | |
| | R6 | SAAD, M. F. <i>et al.</i> "The Natural History of Impaired Glucose Tolerance in the PIMA Indians" <i>New England Journal of Medicine</i> , December 8, 1988, pp. 1500-1506, Vol. 319, No. 23. | |
| | R7 | | |
| | R8 | | |
| | R9 | | |
| | R10 | | |
| | R11 | | |
| | R12 | | |
| | R13 | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.